Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC

BACKGROUND: To date, identifying resectable stage I non-small cell lung cancer (NSCLC) patients likely to benefit from adjuvant therapy (ADT) remains a major challenge. Previous studies suggest that circulating tumor DNA (ctDNA) is emerging as a promising biomarker for NSCLC. However, the effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bolin, Zou, Bing, Xu, Shengnan, Zhao, Chao, Pei, Jinli, Wang, Shijie, Zhao, Kunlong, Yu, Jinming, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895084/
https://www.ncbi.nlm.nih.gov/pubmed/36741027
http://dx.doi.org/10.3389/fonc.2023.1083417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895084/
https://www.ncbi.nlm.nih.gov/pubmed/36741027
http://dx.doi.org/10.3389/fonc.2023.1083417

Ejemplares similares